Taysha Gene Therapies to Participate in Upcoming November Investor Healthcare Conferences

Nov. 8, 2021 12:00 UTC

 

Stifel 2021 Virtual Healthcare Conference on November 15, 2021 at 11:20 am ET

Jefferies London Healthcare Conference November 17, 2021 at 12:20 pm GMT

4th Annual Evercore ISI HealthCONx Virtual Conference on November 30, 2021 at 4:20 pm ET

 

DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies   Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in the Stifel 2021 Virtual Healthcare Conference, Jefferies London Healthcare Conference, and the 4th Annual Evercore ISI HealthCONx Virtual Conference.

Conference Details:

Event:

 

Stifel 2021 Virtual Healthcare Conference

Date:

 

November 15, 2021

Time:

 

11:20 am ET

Format:

 

Fireside Chat

Participants:

 

RA Session II, President, Founder and Chief Executive Officer

 

 

Dr. Suyash Prasad, Chief Medical Officer and Head of R&D

 

 

Kamran Alam, Chief Financial Officer

 

 

Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations

 

 

 

Event:

 

Jefferies London Healthcare Conference

Date:

 

November 17, 2021

Time:

 

12:20 pm GMT

Format:

 

Fireside Chat

Participant:

 

RA Session II, President, Founder and Chief Executive Officer

 

 

Dr. Suyash Prasad, Chief Medical Officer and Head of R&D

 

 

Kamran Alam, Chief Financial Officer

 

 

Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations

 

 

 

Event:

 

4th Annual Evercore ISI HealthCONx Virtual Conference

Date:

 

November 30, 2021

Time:

 

4:20 pm ET

Format:

 

Fireside Chat

Participant:

 

RA Session II, President, Founder and Chief Executive Officer

 

 

Dr. Suyash Prasad, Chief Medical Officer and Head of R&D

 

 

Kamran Alam, Chief Financial Officer

 

 

Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

Contacts

Company Contact:
Kimberly Lee, D.O.
SVP, Corporate Communications and Investor Relations
Taysha Gene Therapies
klee@tayshagtx.com

Media Contact:
Carolyn Hawley
Canale Communications
carolyn.hawley@canalecomm.com

 
 

Source: Taysha Gene Therapies, Inc.

Back to news